Journal of cancer research and therapeutics最新文献

{"title":"Myxoid liposarcoma of thyroid in a 10-year-old child with Li-Fraumeni syndrome: A case report and review of literature.","authors":"Ankita Pandey, Pratibha Prashar, Renu Madan, Narendra Kumar","doi":"10.4103/jcrt.jcrt_1757_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1757_23","url":null,"abstract":"<p><strong>Abstract: </strong>Myxoid liposarcoma of the thyroid is an extremely rare entity seen mostly in the retroperitoneum, extremities, and trunk; however, its occurrence in the head and neck region is reported to be less than 2%. Due to its rarity, evidence-based management is lacking. Here we report a case of a 10-year-old girl with Li-Fraumeni syndrome who presented with a large mass in the thyroid. She underwent hemi-thyroidectomy followed by six cycles of chemotherapy with Ifosfamide and Adriamycin after the histopathologically confirmed diagnosis of myxoid liposarcoma. Within a year, she developed recurrent disease in supraclavicular region and mediastinum, causing superior vena cava obstruction. For this, she received palliative radiotherapy followed by excision of the residual mass and second line chemotherapy. However, the disease progressed and the patient succumbed to the disease within 19 months of diagnosis. In view of the rarity of the condition, the literature does not recommend any standard approach. Surgical excision is a standard first-line approach. As it is difficult to achieve extensive surgical margins in the neck region due to the presence of critical structures in the vicinity, postoperative radiation may improve local control rates.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"299-302"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report of short term EGFR TKI induced tubulointerstitial nephritis and IgA nephropathy in a patient with advanced non small cell lung cancer.","authors":"Ji Eun Park, Jaemin Jo, Sang Hoon Han, Chi Wha Han, Hwa Young Lee, Bo Gun Jang, Dong Hui Lee, Jieun Yang","doi":"10.4103/jcrt.jcrt_430_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_430_24","url":null,"abstract":"<p><strong>Abstract: </strong>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the front-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). Beyond their long-term effects and safety profile, they are a landmark of precision medicine in the history of NSCLC. Regarding safety outcomes, EGER TKIs differ from cytotoxic chemotherapy as they may cause dermatological adverse events, diarrhea, and fetal interstitial pneumonitis. They are mainly metabolized by the liver and to a lesser extent by the kidney and are therefore considered relatively safe to use, even in patients with renal impairment. Moreover, renal adverse events have been rarely described in patients treated with TKIs; in particular, only a few cases of EGFR TKI-induced IgA nephropathy have been reported. Herein, we report a case of EGFR TKI-induced tubulointerstitial nephritis and IgA nephropathy, aggravating renal function with short-term EGFR TKI use in EGFR-mutant NSCLC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"292-294"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The current role of adjuvant radiotherapy in management of medullary thyroid carcinoma: A single institute analysis.","authors":"J Bhuvana, Vinay Shivhare, Satyajeet Rath, Ankita Parikh, U Suryanarayan Kunikullaya","doi":"10.4103/jcrt.jcrt_1174_23","DOIUrl":"10.4103/jcrt.jcrt_1174_23","url":null,"abstract":"<p><strong>Objectives: </strong>Medullary thyroid carcinoma (MTC) accounts for only about 5% of total thyroid cancers. It usually presents as an advanced disease carrying a poor prognosis than well-differentiated thyroid cancers. While the treatment of choice is surgery, the role of adjuvant radiotherapy is still unclear. This retrospective study aims to understand the role of adjuvant radiotherapy in MTC and its effect on survival.</p><p><strong>Materials and methods: </strong>We did a retrospective two study to estimate the effect of adjuvant external beam radiotherapy (EBRT) on survival outcomes in MTC. A total of 30 patients who were diagnosed with nonmetastatic MTC during the period 2015 to 2020 were included in the study. Fifteen patients underwent only total thyroidectomy with cervical lymph node dissection. Rest 15 patients received adjuvant EBRT following surgery. A median dose of 60 Gy in 30 fractions, 2 Gy per fraction, 5 days per week, was given by conventional radiotherapy technique. Survival outcomes were estimated using Kaplan-Meier method. A univariate analysis using log rank test was performed to estimate the association of various prognostic factors including age, sex, tumor size, nodal involvement, and surgical resection status on survival outcomes.</p><p><strong>Results: </strong>Median age of presentation in our study is 47 years (inter quartile range: 36-55 years). Median follow-up time is 4 years. Male to female ratio is 2:3-70% of patients presented with T3 lesions and 77% with N1b disease. There was no significant difference in overall survival (OS) in patients who received adjuvant RT following surgery in comparison to patients who underwent only surgery (92.9% vs. 71.4% P value = 0.202). Similarly, there was no improvement in locoregional recurrence-free survival (LRFS) (100% vs. 85.7%, P value-0.157), Distant metastasis-free survival (DMFS) (64.3% vs. 71.4%, P value = 0.725), and Disease-free survival (DFS) (64.3% vs. 64.3%, P value = 0.91). Age, gender, nodal involvement, and surgical resection status (R0, R1, R2) did not have any effect on survival outcomes. DFS (100% vs. 63.6% P value = 0.008), LRFS (100% vs. 94.7% P value = 0.002), and DMFS (100% vs. 63.2% P value = 0.006) were significantly better in T2 lesions compared to advanced lesions.</p><p><strong>Conclusion: </strong>Adjuvant EBRT failed to show any significant improvement in survival outcomes and locoregional control in MTC. Further prospective randomized clinical trials are needed to validate the role of EBRT in MTC. Clinicians should proceed with caution before advising adjuvant radiotherapy in MTC and make an informed decision after weighing the pros and cons of giving adjuvant EBRT.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"16-21"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiating carcinoma from benign causes of nonspecific gall bladder wall thickening: A prospective observational study on the role of multiparametric MRI and proposition of an MpMRI-based criteria.","authors":"Sudipta Mohakud, Tushar Subhadarshan Mishra, Suprava Naik, Dillip Muduly, Susama Patra, Nerbadyswari Deer Bag, Madhabananda Kar, M Divya, Ranjan Kumar Patel, Tara Prasad Tripathy","doi":"10.4103/jcrt.jcrt_2551_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2551_23","url":null,"abstract":"<p><strong>Background: </strong>In nonspecific gall bladder (GB) wall thickening on ultrasonography (USG) or computed tomography (CT), the patient undergoes a more major surgery for a benign cause or a redo surgery for malignancy if diagnosed inaccurately.</p><p><strong>Purpose: </strong>To evaluate whether malignant and benign causes of nonspecific GB wall thickening can be accurately differentiated on multiparametric magnetic resonance imaging (MpMRI) and to propose MpMRI-based diagnostic criteria.</p><p><strong>Methods: </strong>Thirty-six of 94 nonspecific GB wall thickening patients underwent MpMRI in a 1.5 T scanner. The MRI characterization was compared with histopathology. Statistical analysis calculated various MRI parameters' sensitivity, specificity, and accuracy in distinguishing benign and malignant lesions. The receiver operating curve analysis provided the apparent diffusion coefficient (ADC) cut-off value.</p><p><strong>Results: </strong>MpMRI had 100% sensitivity and 92.31% specificity in detecting malignant wall thickening. The sensitivity and specificity of various parameters like intact mucosa on T2-weighted imaging (T2WI), smooth-enhancing mucosa, identification of wall layers on T2WI, and diffusion-weighted imaging (DWI) were 100% and 84.62%, 100% and 92.31%, 100% and 96.15%, and 100% and 53.85%, respectively, in differentiating benign from malignant thickening. Malignancy showed lower ADC values; the cut-off was 1.107 × 10-3 mm2/s. Intramural nodule/cyst on T2WI, chemical shift imaging, and dynamic contrast-enhanced MRI (DCE-MRI) showed 100% positive predictive value for benign wall thickening.</p><p><strong>Conclusion: </strong>MpMRI accurately differentiates benign from malignant GB wall thickening and is recommended when USG or CT are inconclusive. This will help decide the type of surgery, simple cholecystectomy for benign or radical surgery for a malignant cause. Accurate prediction by MpMRI will reduce patient morbidity and improve survival.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"64-70"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of tumor control probability and normal tissue complication probability in IMRT and VMAT: A comparative study for assessment of efficacy of radiotherapy plans in tumors of the thorax.","authors":"Anoop Kumar Srivastava, Atul Mishra, Sumanta Manna, Neha Yadav, Kailash Kumar Mittal, Surendra Prasad Mishra","doi":"10.4103/jcrt.jcrt_1015_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1015_24","url":null,"abstract":"<p><strong>Objective: </strong>The primary aim of radiation therapy planning is to achieve optimal tumor control probability (TCP) while minimizing the risk of normal tissue complications (NTCPs). Traditionally, the dose-volume histogram has been a reliable tool for evaluating volumetric dose distribution in treatment plans. This study aims to assess the radiobiological efficacy of volumetric modulated arc therapy (VMAT), step-and-shoot intensity-modulated radiation therapy (ss-IMRT), and dynamic IMRT (d-IMRT) in the treatment of thoracic tumors.</p><p><strong>Materials and methods: </strong>This study involved 13 patients diagnosed with squamous cell carcinoma of the thorax. Thirteen patients with squamous cell carcinoma of the thoracic site were included in this study. For each patient, three treatment plans (VMAT, ss-IMRT, and d-IMRT) were created, and the corresponding radiobiological parameters, such as equivalent uniform dose (EUD), TCP, and NTCP, were computed using Niemierko and LKB model for all 39 treatment plans using BIOSUITE software.</p><p><strong>Results: </strong>The estimated average TCPs for ss-IMRT, d-IMRT, and VMAT are 61.51%, 62.86%, and 63.09%, respectively. Moreover, the average NTCPs observed for the organ at risk, lung, for ss-IMRT, d-IMRT, and VMAT were 3.27%, 1.96%, and 1.29%, respectively. In terms of the spinal cord, the average NTCPs for ss-IMRT, d-IMRT, and VMAT were 0.07%, 0.0%, and 0.0%, respectively. For the heart, the average NTCPs for ss-IMRT, d-IMRT, and VMAT were 0.10%, 0.12%, and 0.13%, respectively.</p><p><strong>Conclusions: </strong>The findings of this study suggest that VMAT might give equivalent TCP with less NTCP when compared to IMRT. The development of treatment planning techniques based on radiobiological factors aided in the prudent selection of physical parameters to attain high TCP and low NTCP.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"131-136"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD24 and tumor budding as a prognostic variable in carcinoma gall bladder: A pilot study.","authors":"Devanshi Brajesh Dubey, Preeti Agarwal, Ajay Kumar Singh, Malti Kumar Maurya, Shalini Bhalla, Vishal Gupta, Akshay Anand, Sameer Gupta, Abhinav Arun Sonkar","doi":"10.4103/jcrt.jcrt_1986_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1986_23","url":null,"abstract":"<p><strong>Background: </strong>CD24 is a small heavily glycosylated glycosylphosphotidylinositol-linked cell surface protein that is expressed in a variety of hematological and solid tumors. It is majorly involved in tumor development, proliferation, invasion, metastasis, and prevention of tumor cell death via various major and minor signalling pathways although it can also inhibit invasiveness via degrading BART mRNA.</p><p><strong>Aim and objective: </strong>We aimed to evaluate CD24 expression in gall bladder carcinoma (GBC), via immunohistochemical (IHC) staining on paraffin-embedded histological tissue along with assessment of tumor budding.</p><p><strong>Material and methods: </strong>87 patients were enrolled and CD24 IHC staining was evaluated using four degrees of positivity (negative, mild, moderate, and strong). The expression was then correlated with various clinicopathological parameters. Interpretation was tumor budding was done on the H and E slide. Hotspots were chosen and the total number of buds was reported in an area measuring 0.785 mm2 corresponding to 20× fields in the microscope.</p><p><strong>Results: </strong>CD24 positive expression was found in 77.5% of cases. Its positive expression correlated inversely with tumor stage, necrosis, and lymph vascular invasion establishing its usefulness as a prognostic marker. Tumor budding correlated with poor tumor differentiation and higher tumor grade and poorly differentiated cancer with higher budding responded well to chemotherapy.</p><p><strong>Conclusion: </strong>Our study supports the importance of CD24 and tumor budding as prognostic markers and thus its usefulness in risk stratification in GBC. CD 24 positive subgroup of GBC cases may benefit from anti-CD24 mAb therapy and we also recommend that tumor budding may be included in the morphological synoptic reporting in gall bladder cancer.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"124-130"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High dose rate brachytherapy for vaginal rhabdomyosarcoma in a 10-month-old child using custom-made multi-channel applicator: Initial experience and challenges.","authors":"Renu Madan, Hardik Sharma, Gaganpreet Singh, Arun S Oinam, Rakesh Kapoor, Shikha Goyal, Nitin Peters, Ankita Pandey, Narendra Kumar","doi":"10.4103/jcrt.jcrt_2765_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2765_23","url":null,"abstract":"<p><strong>Abstract: </strong>Brachytherapy plays an important role in the organ preservation strategy in vaginal rhabdomyosarcoma (RMS). Here we report our experience and challenges of high dose rate (HDR) intravaginal brachytherapy (IVBT) in a 10-month-old child, a diagnosed case of localized vaginal RMS with a custom-made applicator and immobilization device. The index case is the first pediatric patient, treated with brachytherapy at our institute.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"77-79"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First clinical experience of total body irradiation using volumetric modulated arc therapy technique in Japan.","authors":"Yuki Nozawa, Hideomi Yamashita, Subaru Sawayanagi, Atsuto Katano","doi":"10.4103/jcrt.jcrt_1067_23","DOIUrl":"10.4103/jcrt.jcrt_1067_23","url":null,"abstract":"<p><strong>Abstract: </strong>In recent years, advances in radiotherapy technology have led to the use of high-precision radiotherapy such as volumetric modulated arc therapy (VMAT). Total body irradiation using VMAT technique (VMAT-TBI) was performed for the first time in our hospital. A 56-year-old male patient diagnosed with B-cell acute lymphoblastic leukemia was performed TBI as pretreatment for haploidentical-related peripheral blood stem-cell transplantation. The prescribed dose was 4 Gy for planning target volume in two fractions. The treatment plan was divided into two plans: upper body and lower body with three and two isocenters, respectively. The overall treatment time with VMAT-TBI was approximately 55 min, and it was not significantly longer than that of moving couch techniques. VMAT-TBI is a less burdensome and more accurate treatment for patients, and it may be a useful treatment for TBI.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"237-239"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Periprosthetic metastases in carcinoma of unknown primary: A rare association.","authors":"Aditya Singla, Shikha Goyal, Saikat Mitra, Rajender Kumar, Kannan Periasamy, Amanjit Bal, Renu Madan, Divya Khosla","doi":"10.4103/jcrt.jcrt_526_22","DOIUrl":"10.4103/jcrt.jcrt_526_22","url":null,"abstract":"<p><strong>Abstract: </strong>Septic or aseptic loosening may cause bone loss around artificial prosthesis leading to prosthesis failure. This occurrence due to metastatic infiltration of bone or surrounding soft tissues is rare but has been occasionally reported. We report a case of an elderly lady presenting with swelling and pain at the site of previous hemiarthroplasty performed for traumatic injury. On evaluation, she was found to have a lytic femur lesion with a large soft-tissue component around the prosthetic joint. Biopsy suggested a metastatic carcinoma of renal origin, but screening of kidneys did not reveal any primary lesion. She had additional skeletal metastatic lesions but no other primary site was detected either. She was given palliative radiotherapy and systemic therapy (sunitinib) based on the histologic diagnosis of renal cell origin but did not tolerate it. Thereafter, she is continuing on zoledronate every 4 weeks and best supportive management since 4 months from diagnosis.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"212-214"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139543716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of TERT promoter mutation and its association with clinicopathologic factors in papillary thyroid carcinoma in Kerala population.","authors":"Dhanya Krishnan, Sandeep Suresh, Nebu A George, K R Anila, S Kannan","doi":"10.4103/jcrt.jcrt_460_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_460_24","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of papillary thyroid cancer (PTC) is increasing in India and other high-income countries. A high prevalence of thyroid cancer has been reported in Kerala-a state in southern India. A significant conclusion is that Thiruvananthapuram, the capital of Kerala, ranks first among males and second among women in terms of the incidence of TC in India.</p><p><strong>Objectives: </strong>The objective of this study was to investigate the clinical significance of TERT Promoter mutations in thyroid carcinoma. Specifically, this study aimed to determine the prevalence of TERT promoter mutations in a cohort of patients with thyroid carcinoma and analyze the association between TERT Promoter mutations and clinicopathological characteristics of thyroid carcinoma.</p><p><strong>Materials and methods: </strong>In this study, patients with PTC were enrolled between 2020 and 2021. Mutation analysis of TERT gene promoter was successfully performed in 47 patients using the PCR amplification of TERT promoter region followed by direct sequencing.</p><p><strong>Results: </strong>PTC harboring TERT Promoter mutation was detected in 18 out of 47 patients (38%). The presence of TERT promoter mutations and various clinicopathological characteristics were compared. Statistical analysis reveals that the clinicopathological parameters, such as clinical as well as pathological stage of disease have significant association with the TERT promoter mutations.</p><p><strong>Conclusions: </strong>These findings highlight the potential of TERT promoter mutations as valuable prognostic indicators and suggest their potential utility as therapeutic targets in PTC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"80-84"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}